Trial · NCT00262821
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival - Percentage of Patients Alive and Progression Free | Concurrent Cisplatin and Radiation | 64.4 | percentage of patients | ||
| Progression-free Survival - Percentage of Patients Alive and Progression Free | Concurrent Cisplatin, Tirapazamine and Radiation | 63.0 | percentage of patients | ||
| Overall Survival | Concurrent Cisplatin and Radiation | 70.6 | percentage of patients alive | ||
| Overall Survival | Concurrent Cisplatin, Tirapazamine and Radiation | 70.5 | percentage of patients alive | ||
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Number Participants Analyzed | 190 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Number Participants Analyzed | 180 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Leukopenia | 51 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Leukopenia | 53 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Thrombocytopenia | 8 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Thrombocytopenia | 6 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Neutropenia | 30 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Neutropenia | 26 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Anemia | 16 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Anemia | 12 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Other hematologic | 20 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Other hematologic | 17 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Allergy/Immunology | 0 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Allergy/Immunology | 2 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin and Radiation | Cardiac | 3 | participants | |
| Adverse Events (Grade 3 or Higher) During Treatment Period | Concurrent Cisplatin, Tirapazamine and Radiation | Cardiac | 4 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00262821/results